Adverse events associated with discontinuation of the biologics/classic systemic treatments for moderate-to-severe plaque psoriasis: data from the Spanish Biologics Registry, Biobadaderm

Autor: Belinchon I, Ramos J, Carretero, G, Ferrandiz, C, Rivera, R, Dauden, E, De la Cueva-Dobao, P, Gomez-Garcia, F, Herrera-Ceballos, E, Sanchez-Carazo, J, Lopez-Estebaranz, J, Alsina, M, Ferran, M, Torrado, R, Carrascosa, J, Llamas-Velasco, M, Ortiz, P, Garcia-Doval, I, Descalzo, M, Biobadaderm Study Grp
Rok vydání: 2017
Zdroj: JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
r-ISABIAL. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica y Sanitaria de Alicante
instname
r-FISABIO: Repositorio Institucional de Producción Científica
Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO)
ISSN: 0926-9959
Popis: BackgroundLittle is known about the adverse events (AEs) that lead to suspension of systemic treatments for psoriasis in clinical practice. ObjectiveThe study aimed to investigate AEs associated with discontinuation of systemic therapy in patients with psoriasis in a clinical setting (Biobadaderm). Materials and methodsMulticentre, prospective, cohort study of patients with moderate-to-severe plaque psoriasis receiving systemic therapies from January 2008 to November 2015, in 12 hospitals in Spain. The incidence rate (IR) was used to compare biologics and classic systemic therapies. ResultsA total of 4218 courses of treatment were given to 1938 patients. A total of 447 (11%) treatments were discontinued due to AEs. The IR of AE associated with discontinuation of systemic therapies was 13 events/100 patient-years (PY) (95% CI: 12.14-13.93), 9.34 events/100 PY (95% CI: 8.44-10.33) for biologics and 19.67 (95% CI: 17.9-21.6) events/100 PY for classics (P
Databáze: OpenAIRE
Externí odkaz: